Outcomes with single agent LIPO-DOX in platinum-resistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital experience

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 3, 2014, Pages 1145-1148

  Suprasert, Prapaporn ^a   Manopunya, Manatsawee ^a   Cheewakriangkrai, Chalong ^b  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

LIPO DOX; Outcome; Platinum resistant ovarian cancer; Toxicity

Indexed keywords

DOXORUBICIN; DRUG DERIVATIVE; MACROGOL DERIVATIVE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; DISEASE FREE SURVIVAL; DRUG RESISTANCE; FEMALE; HUMAN; MIDDLE AGED; OVARY TUMOR; PERITONEUM TUMOR; RETROSPECTIVE STUDY; SALVAGE THERAPY; THAILAND; TREATMENT OUTCOME; TUMOR RECURRENCE; UNIVERSITY HOSPITAL; UTERINE TUBE TUMOR;

ADENOCARCINOMA; ADULT; AGED; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FALLOPIAN TUBE NEOPLASMS; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; THAILAND; TREATMENT OUTCOME;

EID: 84896820972     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.3.1145     Document Type: Article

References (12)

1. Bast RC Jr, Markman M (2010). Chemotherapy: A new standard combination for recurrent ovarian cancer? Nat Rev Clin Oncol, 7, 559-60.
2. Ferrandina G, Ludovisi M, Lorusso D, et al (2008). Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol, 26, 890-6.
3. Gordon AN, Granai CO, Rose PG, et al(2000). Phase II study of liposomal doxorubicin in platinum-and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol, 18, 3093-100.
4. Hsiao SM, Chen CA, Lin HH, et al (2009). Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinumsensitive ovarian cancer following front-line therapy with paclitaxel and platinum. Gynecol Oncol, 112, 35-9.
5. Khemapech N, Oranratanaphan S, Termrungruanglert W, et al (2013). Salvage chemotherapy in recurrent platinumresistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®). Asian Pac J Cancer Prev, 14, 2131-5.
6. Markman M (2011). Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer. Cancer Manag Res, 3, 219-25.
7. Mutch DG, Orlando M, Goss T, et al (2007). Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol, 25, 2811-8.
8. Miller AB, Hoogstraten B, Staquet M, et al (1981). Reporting results of cancer treatment. Cancer, 47, 207-14.
9. Naumann RW, Coleman RL (2011). Management strategies for recurrent platinum-resistant ovarian cancer. Drugs, 71, 1397-412.
10. Pectasides D, Psyrri A, Pectasides M, et al (2006). Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan? Expert Opin Pharmacother, 7, 75-87.
11. Rustin GJ, Vergote I, Eisenhauer E, et al (2011). Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer, 21, 419-23.
12. Taiwanese Gynecologic Oncology Group, Chou HH, Wang KL, et al (2006). Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with longterm follow-up. Gynecol Oncol, 101, 423-8.